Quantcast

Arbor Pharmaceuticals Announces the Launch of ZINOTIC ES – A New Extra Strength Product for the Treatment of Acute Otitis Externa

June 2, 2009

RALEIGH, N.C., June 2 /PRNewswire/ — Arbor Pharmaceuticals (“Arbor”), a specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company has launched ZINOTIC ES as a new treatment option for Acute Otitis Externa (AOE). ZINOTIC ES is an extra strength formulation of original ZINOTIC intended to provide children suffering from AOE with a greater degree of pain relief and skin protection. ZINOTIC ES is Arbor Pharmaceuticals’ fourth product launch in the U.S. and is now available by prescription from retail pharmacies across the U.S.

AOE or “swimmer’s ear” is a common childhood infection of the ear canal characterized by intense pain and inflamed, damaged skin. Children are most susceptible to AOE, and swimming is the most common predisposing factor for acquiring the infection. When treating AOE there are three main goals to address including treating the infection, relieving the pain and restoring the integrity of the lining of the ear canal. ZINOTIC is the only family of products that addresses the three AOE treatment goals. ZINOTIC ES contains the maximum dose of pramoxine and a higher level of zinc acetate to enable greater pain relief and skin protection while treating the infection without an antibiotic.

“ZINOTIC has become an important AOE treatment option since its introduction, and new ZINOTIC ES will be a welcome addition to the ZINOTIC franchise as it further addresses the three AOE treatment goals with its enhanced, extra strength formulation,” according to Jarrett Disbrow, President and CEO of Arbor Pharmaceuticals. “The launch of ZINOTIC ES demonstrates the company’s ongoing dedication to enhancing pediatric medicine. Arbor will continue to build its portfolio of pediatric pharmaceuticals focused on providing novel prescription products for the most common pediatric illnesses.”

ZINOTIC ES is being promoted to U.S. pediatricians by Arbor Pharmaceuticals’ sales force and via partner companies in select regions of the U.S. For more information about ZINOTIC ES, visit www.zinotic.com. The most common side effects of pramoxine (contained in ZINOTIC ES) include redness, irritation, swelling, burning, stinging, pain or dryness at the affected area.

About Arbor Pharmaceuticals

Arbor Pharmaceuticals is a Raleigh, North Carolina-based specialty pharmaceutical company focused exclusively on the growing pediatric market. The company is well positioned to become the leading pediatrics-focused pharmaceutical company by actively licensing, developing and commercializing late-stage products for common pediatric conditions. The company currently focuses on nonantibiotic products for ear infections including ZINOTIC for acute otitis externa, XYLAREX for the dietary management of recurrent ear infections and NEOTIC for acute otitis media. Arbor is also building a pipeline of other promising products for the most common pediatric illnesses. To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

SOURCE Arbor Pharmaceuticals


Source: newswire



comments powered by Disqus